2-[(18S,25S,35S)-35-[(S)-hydroxy(phenyl)methyl]-28-(methoxymethyl)-21-methyl-18-[2-(methylamino)-2-oxoethyl]-16,23,30,33-tetraoxo-25-propan-2-yl-3,13,20,27,37-pentathia-7,17,24,31,34,39,40,41,42,43-decazaheptacyclo[34.2.1.12,5.112,15.119,22.126,29.06,11]tritetraconta-1(38),2(43),4,6(11),7,9,12(42),14,19(41),21,26(40),28,36(39)-tridecaen-8-yl]-1,3-thiazole-4-carboxylic acid | 960062-64-0

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 大环内酰胺类
• 英文名称: 2-[(18S,25S,35S)-35-[(S)-hydroxy(phenyl)methyl]-28-(methoxymethyl)-21-methyl-18-[2-(methylamino)-2-oxoethyl]-16,23,30,33-tetraoxo-25-propan-2-yl-3,13,20,27,37-pentathia-7,17,24,31,34,39,40,41,42,43-decazaheptacyclo[34.2.1.12,5.112,15.119,22.126,29.06,11]tritetraconta-1(38),2(43),4,6(11),7,9,12(42),14,19(41),21,26(40),28,36(39)-tridecaen-8-yl]-1,3-thiazole-4-carboxylic acid
• CAS: 960062-64-0
• 化学式: C₄₈H₄₄N₁₂O₉S₆
• 分子量: 1125.35
• InChiKey: FQPTUJKBHPYRON-BMHVMUFNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  75
• 可旋转键数：
  9
• 环数：
  9.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  472
• 氢给体数：
  7
• 氢受体数：
  22

反应信息

• 作为反应物：
  描述：

  2-[(18S,25S,35S)-35-[(S)-hydroxy(phenyl)methyl]-28-(methoxymethyl)-21-methyl-18-[2-(methylamino)-2-oxoethyl]-16,23,30,33-tetraoxo-25-propan-2-yl-3,13,20,27,37-pentathia-7,17,24,31,34,39,40,41,42,43-decazaheptacyclo[34.2.1.12,5.112,15.119,22.126,29.06,11]tritetraconta-1(38),2(43),4,6(11),7,9,12(42),14,19(41),21,26(40),28,36(39)-tridecaen-8-yl]-1,3-thiazole-4-carboxylic acid 在 吡啶 、 盐酸 、 4-二甲氨基吡啶 、 sodium azide 、 caesium carbonate 、 三乙胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 、 丙酮 为溶剂， 反应 20.33h， 生成
  参考文献：
  名称：

  Discovery of LFF571: An Investigational Agent for Clostridium difficile Infection

  摘要：

  Clostridium difficile (C. difficile) is a Gram positive, anaerobic bacterium that infects the lumen of the large intestine and produces toxins. This results in a range of syndromes from mild diarrhea to severe toxic megacolon and death. Alarmingly, the prevalence and severity of C. difficile infection are increasing; thus, associated morbidity and mortality rates are rising. 4-Aminothiazolyl analogues of the antibiotic natural product GE2270 A (1) were designed, synthesized, and optimized for the treatment of C. difficile infection. The medicinal chemistry effort focused on enhancing aqueous solubility relative to that of the natural product and previous development candidates (2, 3) and improving antibacterial activity. Structure-activity relationships, cocrystallographic interactions, pharmacokinetics, and efficacy in animal models of infection were characterized. These studies identified a series of dicarboxylic acid derivatives, which enhanced solubility/efficacy profile by several orders of magnitude compared to previously studied compounds and led to the selection of LFF571 (4) as an investigational new drug for treating C. difficile infection.

  DOI：

  10.1021/jm201685h
• 作为产物：
  描述：

  GE2270 A 在 水 、 sodium hydroxide 作用下， 以 四氢呋喃 为溶剂， 反应 1.5h， 生成 2-[(18S,25S,35S)-35-[(S)-hydroxy(phenyl)methyl]-28-(methoxymethyl)-21-methyl-18-[2-(methylamino)-2-oxoethyl]-16,23,30,33-tetraoxo-25-propan-2-yl-3,13,20,27,37-pentathia-7,17,24,31,34,39,40,41,42,43-decazaheptacyclo[34.2.1.12,5.112,15.119,22.126,29.06,11]tritetraconta-1(38),2(43),4,6(11),7,9,12(42),14,19(41),21,26(40),28,36(39)-tridecaen-8-yl]-1,3-thiazole-4-carboxylic acid
  参考文献：
  名称：

  天然产物GE2270 A的4-氨基噻唑基类似物的抗菌优化：环烷基羧酸的鉴定

  摘要：

  设计，合成和优化了抗生素天然产物GE2270 A（1）的4-氨基噻唑类似物，以抵抗革兰氏阳性细菌感染。优化工作着重于提高4-氨基噻唑基天然产物模板的理化性质（例如，水溶性和化学稳定性），同时提高体外和体内的抗菌活性。定义了结构活性关系，并且溶解度和功效谱比以前的类似物和1有所改善。这些研究确定了具有环烷基羧酸侧链的新型，有效，可溶和有效的伸长因子Tu抑制剂，并最终选择了开发候选酰胺48。和氨基甲酸酯58。

  DOI：

  10.1021/jm200938f

文献信息

• EFTU INHIBITORS OR AMINOTHIAZOLES AND THEIR USES
  申请人：LaMarche Matthew J.

  公开号：US20080221142A1

  公开（公告）日：2008-09-11

  The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of diseases.

  本申请描述了对治疗、预防和/或改善疾病有用的有机化合物。
• Antibacterial Optimization of 4-Aminothiazolyl Analogues of the Natural Product GE2270 A: Identification of the Cycloalkylcarboxylic Acids
  作者：Matthew J. LaMarche、Jennifer A. Leeds、Kerri Amaral、Jason T. Brewer、Simon M. Bushell、Janetta M. Dewhurst、JoAnne Dzink-Fox、Eric Gangl、Julie Goldovitz、Akash Jain、Steve Mullin、Georg Neckermann、Colin Osborne、Deborah Palestrant、Michael A. Patane、Elin M. Rann、Meena Sachdeva、Jian Shao、Stacey Tiamfook、Lewis Whitehead、Donghui Yu

  DOI：10.1021/jm200938f

  日期：2011.12.8

  4-Aminothiazolyl analogues of the antibiotic natural product GE2270 A (1) were designed, synthesized, and optimized for their activity against Gram positive bacterial infections. Optimization efforts focused on improving the physicochemical properties (e.g., aqueous solubility and chemical stability) of the 4-aminothiazolyl natural product template while improving the in vitro and in vivo antibacterial

  设计，合成和优化了抗生素天然产物GE2270 A（1）的4-氨基噻唑类似物，以抵抗革兰氏阳性细菌感染。优化工作着重于提高4-氨基噻唑基天然产物模板的理化性质（例如，水溶性和化学稳定性），同时提高体外和体内的抗菌活性。定义了结构活性关系，并且溶解度和功效谱比以前的类似物和1有所改善。这些研究确定了具有环烷基羧酸侧链的新型，有效，可溶和有效的伸长因子Tu抑制剂，并最终选择了开发候选酰胺48。和氨基甲酸酯58。
• Aminothiazoles and their Uses
  申请人：Bushell Simon

  公开号：US20090156628A1

  公开（公告）日：2009-06-18

  The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of diseases particularly bacterial infections.

  本申请描述了对治疗、预防和/或改善疾病特别是细菌感染有用的有机化合物。
• 4-Aminothiazolyl Analogues of GE2270 A: Antibacterial Lead Finding
  作者：Matthew J. LaMarche、Jennifer A. Leeds、JoAnne Dzink-Fox、Karl Gunderson、Philipp Krastel、Klaus Memmert、Michael A. Patane、Elin M. Rann、Esther Schmitt、Stacey Tiamfook、Bing Wang

  DOI：10.1021/jm101602q

  日期：2011.4.14

  4-Aminothiazolyl analogues of the antibacterial natural product GE2270 A (1) were designed, synthesized, and evaluated for Gram positive bacteria growth inhibition. The aminothiazole-based chemical template was evaluated for chemical stability, and its decomposition revealed a novel, structurally simplified, des-thiazole analogue of 1. Subsequent stabilization of the 4-aminothiazolyl functional motif was achieved and initial structure activity relationships defined.
• Discovery of LFF571: An Investigational Agent for <i>Clostridium difficile</i> Infection
  作者：Matthew J. LaMarche、Jennifer A. Leeds、Adam Amaral、Jason T. Brewer、Simon M. Bushell、Gejing Deng、Janetta M. Dewhurst、Jian Ding、JoAnne Dzink-Fox、Gabriel Gamber、Akash Jain、Kwangho Lee、Lac Lee、Troy Lister、David McKenney、Steve Mullin、Colin Osborne、Deborah Palestrant、Michael A. Patane、Elin M. Rann、Meena Sachdeva、Jian Shao、Stacey Tiamfook、Anna Trzasko、Lewis Whitehead、Aregahegn Yifru、Donghui Yu、Wanlin Yan、Qingming Zhu

  DOI：10.1021/jm201685h

  日期：2012.3.8

  Clostridium difficile (C. difficile) is a Gram positive, anaerobic bacterium that infects the lumen of the large intestine and produces toxins. This results in a range of syndromes from mild diarrhea to severe toxic megacolon and death. Alarmingly, the prevalence and severity of C. difficile infection are increasing; thus, associated morbidity and mortality rates are rising. 4-Aminothiazolyl analogues of the antibiotic natural product GE2270 A (1) were designed, synthesized, and optimized for the treatment of C. difficile infection. The medicinal chemistry effort focused on enhancing aqueous solubility relative to that of the natural product and previous development candidates (2, 3) and improving antibacterial activity. Structure-activity relationships, cocrystallographic interactions, pharmacokinetics, and efficacy in animal models of infection were characterized. These studies identified a series of dicarboxylic acid derivatives, which enhanced solubility/efficacy profile by several orders of magnitude compared to previously studied compounds and led to the selection of LFF571 (4) as an investigational new drug for treating C. difficile infection.